A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age. (Q41060727)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

26 September 2017

A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age. (English)

1 reference

Europe PubMed Central

26 September 2017

maternal health

0 references

0 references

4

object named as

Gale Smith

1 reference

Europe PubMed Central

26 September 2017

author name string

Gregory M Glenn

1

1 reference

Europe PubMed Central

26 September 2017

Louis F Fries

2

1 reference

Europe PubMed Central

26 September 2017

D Nigel Thomas

3

1 reference

Europe PubMed Central

26 September 2017

Eloi Kpamegan

5

1 reference

Europe PubMed Central

26 September 2017

Hanxin Lu

6

1 reference

Europe PubMed Central

26 September 2017

David Flyer

7

1 reference

Europe PubMed Central

26 September 2017

Dewal Jani

8

1 reference

Europe PubMed Central

26 September 2017

Somia P Hickman

9

1 reference

Europe PubMed Central

26 September 2017

Pedro A Piedra

10

1 reference

Europe PubMed Central

26 September 2017

language of work or name

0 references

publication date

10 August 2015

1 reference

Europe PubMed Central

26 September 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

Journal of Infectious Diseases

1 reference

Europe PubMed Central

26 September 2017

213

1 reference

Europe PubMed Central

26 September 2017

3

1 reference

Europe PubMed Central

26 September 2017

411-422

1 reference

Europe PubMed Central

26 September 2017

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Risk of primary infection and reinfection with respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Gene sequence variability of the three surface proteins of human respiratory syncytial virus (HRSV) in Texas

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Serum antibody decay in adults following natural respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Interventions to reduce neonatal mortality from neonatal tetanus in low and middle income countries--a systematic review

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Neonatal outcomes after antenatal influenza immunization during the 2009 H1N1 influenza pandemic: impact on preterm birth, birth weight, and small for gestational age birth

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Effectiveness of maternal influenza immunization in mothers and infants

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

IgG placental transfer in healthy and pathological pregnancies

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Transplacental transport of IgG antibodies to preterm infants: a review of the literature

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Respiratory syncytial virus: an important cause of acute respiratory illness among young adults undergoing military training

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Symptomatic respiratory syncytial virus infection in previously healthy young adults living in a crowded military environment

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV406

21 January 2018

Identifiers

10.1093/INFDIS/JIV406

1 reference

Europe PubMed Central

26 September 2017

1 reference

Europe PubMed Central

26 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41060727&oldid=1817196402"